Trending Now

The Secret to Success with Trade Secrets – 5 Factors That Litigation Funders Should Consider When Evaluating Trade Secrets Cases

The Secret to Success with Trade Secrets – 5 Factors That Litigation Funders Should Consider When Evaluating Trade Secrets Cases

The following article is a contribution from Ben Quarmby and Jonathan E. Barbee, Partner and Counsel at MoloLamken LLP, respectively.  Litigation funders have trade secrets on their minds.  Since the introduction of the Defend Trade Secrets Act (DTSA) in 2016, trade secrets litigation has been on the rise.  Over a thousand trade secrets cases were filed in federal court in both 2021 and 2022.  By all accounts, that trend is set to continue.  Big verdicts have followed, with some trade secrets verdicts now rivaling the biggest patent verdicts.  In the information age, a company’s most valuable intellectual property may not be its patents after all, but the wealth of non-patented, proprietary information surrounding its ideas—its trade secrets. Trade secrets cases can be more attractive to litigation funders than patent cases.  The funding of patent deals is regularly scuttled by patent expirations, validity concerns (especially Section 101 patent eligibility concerns), the threat of inter partes reviews (IPRs) at the United States Patent and Trademark Office, and the perceived focus of the Federal Circuit on reversing the largest patent verdicts that come before it.  Trade secrets side-step many of these issues.  They do not expire.  They are less likely to be sunk by an obscure prior art reference.  They are not subject to IPR proceedings.  And they are generally not subject to scrutiny by the Federal Circuit.  They also offer many of the same benefits to plaintiffs as patent cases: they too can be rooted in invention stories that will resonate with juries and lead to exemplary damages. They offer their own challenges, of course.  Unlike patent cases, there is no “innocent” misappropriation with trade secrets.  A defendant must often come into contact with the plaintiff’s trade secrets for a claim to arise.  Successful trade secret claims usually require a chain of events that put the trade secrets in the hands of the defendant.  Patent plaintiffs do not face those hurdles. Finding promising trade secrets cases requires identifying the types of companies that will regularly find themselves in situations that lead to trade secret misappropriation: joint ventures, startups seeking investment by larger industry players, acquisition targets, and companies operating in industries with high employee turnover and mobility.  And once those cases are found, performing due diligence on them requires a very specific type of focus. The following steps are critical:
  • Identify the Trade Secrets. Ensure at the outset that there are clean, concrete, and well-defined trade secrets to assert.  In some jurisdictions, plaintiffs must identify their trade secrets before proceeding with discovery—failure to do so with sufficient precision can stop the litigation dead in its tracks.  If plaintiffs can clearly identify the form of the trade secrets (e.g., scientific data, customer lists, product recipes, hard copy documents, etc.), the chain of custody for those trade secrets, and any changes made to the trade secrets over time, their case is far more likely to withstand the test of litigation.
  • Verify the Plaintiff’s Protective Measures. Defendants will generally argue that a plaintiff has not taken adequate steps to protect its trade secrets.  You need a clean and clear story to tell about the steps a plaintiff has taken to protect its intellectual property.  Tangible evidence of such steps—company policies, firewalls, passwords—is invaluable.  And there should be a narrow or controlled universe of third parties—if any—with whom the information has been shared.  Each additional third party with access to the information can increase the uncertainty surrounding the trade secrets and affect the value of the case.
  • Estimate the Value of Trade Secrets. Calculating damages in trade secrets cases can be trickier than in patent cases.  It is harder to find comparable licenses or valuations for similar types of trade secrets since trade secrets are just that—secret.  There are also fewer established damages methodologies in trade secrets cases.  While this allows for more flexibility and creativity in crafting a damages theory, it can also make trade secret damages susceptible to challenges.  The Georgia-Pacific factors used so often in patent cases can help determine reasonable royalty rates in trade secrets cases, but courts have yet to adopt those factors as the definitive standard for trade secrets.  In conducting due diligence, hire a damages expert to estimate the value of trade secrets before filing a case.
  • Assess the Value of Injunctive Relief. Trade secrets cases are often better candidates for injunctive relief than patent cases.  Determine the strength of a case’s injunctive relief prospects early on.  The likelihood of injunctive relief has to be factored into the economic value of a trade secrets case, since it will directly impact the likelihood of early settlement.
  • Determine the Narrative. Storytelling matters in every IP case.  But it perhaps matters in trade secrets cases even more so.  It is imperative to have reliable witnesses who can illustrate the plaintiff’s narrative in a compelling and clean way.  Test the potential witnesses before considering funding.  Let them tell their story—and challenge that story—under conditions that will most closely approximate those at trial.  Attractive cases should tell a persuasive story about how the trade secrets reflect plaintiffs’ know-how, experience, and competitive edge, and also expose the motives for defendants to steal those trade secrets.
These considerations are a starting point.  Due diligence should be tailored to the particular facts and nuances of each potential trade secrets case.  Careful consideration of these factors will help ensure that funders make the wisest investments, while avoiding common pitfalls in trade secrets litigation.

Commercial

View All

Litigation Capital Management Secures Further Covenant Waiver Extension

Litigation Capital Management has obtained another short extension of the covenant waiver on its debt facility with Northleaf Capital Partners, moving the expiry date from 13 November 2026 to 27 November 2026.

As reported by Investegate, the AIM-quoted funder disclosed the extension in a regulatory announcement released on 16 November 2026. Interest on the loan remains increased by 2.00% per annum for the duration of the extension, and no additional one-time waiver fee is payable.

The move continues a sequence of short-dated waivers the company has disclosed through the second half of 2026. Earlier extensions carried the waiver to the end of September and then to 13 November, with each announcement arriving close to the preceding deadline.

Covenant waivers give a borrower temporary relief from financial tests attached to a facility. For a litigation funder, cash flows depend on the timing of case resolutions, which cannot be scheduled with precision, so covenant headroom is closely linked to the pace at which concluded matters convert into cash.

Litigation Capital Management has not disclosed further detail on the facility or on the discussions behind the extension. The current waiver runs to 27 November 2026.

UK Campaign to Ban “No Win, No Fee” Advertising Also Seeks Funder Regulation

A new UK campaign calling for a ban on "no win, no fee" advertising has coupled that demand with a call for statutory regulation of litigation funding, placing the funding industry alongside claims advertising as a consumer protection concern.

As reported by Legal Futures, the campaign was launched by Fair Civil Justice with a film screened in Parliament. The group is led by executive director Seema Kennedy, a former Conservative MP. It is pressing three demands: a ban on the term "no win, no fee" in advertising for consumer claims by law firms and claims management companies; statutory regulation of litigation funding; and clear information on costs before a consumer agrees to pursue a claim.

Kennedy said the Civil Justice Council's June 2025 report, which recommended "light touch" regulation of the funding sector, could serve "as a blueprint." The Ministry of Justice indicated in January 2026 that it would introduce a framework along those lines.

The campaign cites Solicitors Regulation Authority research published in July 2026 finding that only 21% of consumers learned the potential costs of a claim before signing. It also points to the collapse of SSB Law, after which homeowners faced legal bills of up to £70,000. Fair Civil Justice counts the British and US Chambers of Commerce among its members, and the SSB Law Victims Group and Divorce Without Debt among supporting groups. Labour MP for Burnley Oliver Ryan is also involved, with the campaign referencing the roles of the SRA and the Legal Services Board.

The Consumer Legal Association opposed the campaign, saying it ignores regulatory failures and would restrict access to justice.

Woodsford’s David Haughan Warns Funder Regulation Could Cut Competition and Raise Pricing

A senior Woodsford executive has set out how the funder picks cases, where he sees growth, and why he is wary of statutory regulation of UK litigation funding.

In an interview published by Hogan Lovells Cadwalader, conducted by Valerie Kenyon and Olivier Swain, David Haughan, senior investment officer at Woodsford, said the firm has focused on group claims since around 2019. Its core UK work is in Competition Appeal Tribunal claims and shareholder actions under sections 90 and 90A of FSMA, alongside class actions in Australia, New Zealand, Canada and the Netherlands. Woodsford also now offers services on cases it does not fund, including bookbuilding for securities claims.

On case selection, Haughan said the firm declines quickly in unfamiliar jurisdictions or where a defendant could not realistically pay, adding that "the merits of the claim are by far the most important factor."

He cautioned that "the most likely consequence of a regulatory regime is that it would reduce competition in the litigation funding market by creating barriers to entry and regulatory risk for new, or less specialised, litigation funders," urging policymakers to weigh the benefits against "an increase in pricing."

Looking ahead, Haughan said he expects continued growth in securities litigation and "some consolidation in the market within the next five years." He added that an opt-out consumer class actions regime "would materially increase our appetite to invest in product liability and environmental claims in the UK."

On control, he said Woodsford has the right to be kept informed, but "the claimants have authority over the settlement."